Understanding the colloidal stability of protein therapeutics using dynamic light scattering
White Paper Jul 10, 2014
The combination of dynamic light scattering (DLS) with Raman spectroscopy provides the ability to extract a wealth of chemical, structural, and physical information about biotherapeutic proteins under formulation conditions.
Dynamic light scattering (DLS) using noninvasive backscatter (NIBS) detection technology is capable of measuring the hydrodynamic radius of proteins over a large concentration range (0.1 mg/mL to 100 mg/mL). As a result, it is possible to determine, in actual biopharmaceutical formulations, the bulk viscosity/restricted diffusion interaction parameter (kD), particle interaction parameter (B22), melting temperature, onset temperature of protein aggregation and transition enthalpies to assess colloidal stability.
The unique coupling of DLS with Raman spectroscopy provides the ability to simultaneously correlate colloidal parameters to protein structure under a variety of stress conditions, e.g., thermal, formulation, chemical degradation, extrinsic particulates, to enhance our understanding of protein therapeutic formulations.
Related White Papers
Single-cell sequencing is quickly becoming a standard tool in biological research due to the scale and depth of insight it provides across diverse cell populations. The pharmaceutical industry is exploiting single-cell approaches to identify novel therapeutic targets and accelerate promising assets through development.READ MORE
The rapid and cost-effective production of conventional monoclonal antibodies (mAbs) for clinical trials has contributed toward their wide adoption. As the number of next-generation antibody-based candidates with modified or absent Fc domains increases, biomanufacturers face a need to establish alternative affinity purification technologies.READ MORE
Over the past two decades, monoclonal antibodies (mAbs) have been one of the most dominant segments of the biotherapeutics market. Ensuring mAbs’ safety and efficacy is vital but is made complicated by the fact that antibodies can have a tendency to aggregate during production, decreasing efficacy and increasing the risk of immunogenicity.READ MORE